Daclatasvir Tablet A Groundbreaking Antiviral Solution in Hepatitis C Care

Daclatasvir Tablet is a prescription antiviral medication that has revolutionized the treatment of chronic Hepatitis C Virus (HCV) infections. As an NS5A inhibitor, it interferes with a vital protein necessary for HCV replication and assembly, making it a cornerstone in combination regimens for achieving sustained virologic response (SVR). Manufactured under various brand names, including the widely recognized Daklinza and generics such as Natdac, Daclatasvir has been integrated into standard treatment protocols across the globe. What makes Daclatasvir particularly impactful is its oral administration, eliminating the need for painful injections that were standard in earlier therapies. Furthermore, it works across various HCV genotypes, a feature that adds versatility and convenience to clinical decision-making. Healthcare professionals now regard it as a first-line agent, thanks to its proven track record of safety, potency, and high cure rates even among patients with complex conditions like cirrhosis or HIV co-infection. ________________________________________ 2. Composition and Pharmacokinetics Each Daclatasvir tablet contains 60 mg of Daclatasvir dihydrochloride, equivalent to 60 mg of Daclatasvir as the active component. The formulation is specifically designed to ensure rapid and efficient absorption in the gastrointestinal tract, making it ideal for once-daily oral dosing. Pharmacokinetic Highlights: • Absorption: Peak plasma concentrations are typically achieved within 1–2 hours post-dose. • Bioavailability: Estimated at approximately 67%, allowing consistent therapeutic levels. • Distribution: Daclatasvir exhibits a high degree of plasma protein binding (~99%), indicating effective tissue penetration. • Metabolism: It is primarily metabolized by CYP3A4 enzymes in the liver. • Elimination: About 88% is eliminated via feces and only 6.6% through urine, which supports its use in renal-impaired patients.